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Abstract— This paper is the result of a literature review 
focusing on the application of process analytical technology 
(PAT) for the pharmaceutical industry in conjunction with the 
quality by design (QBD) framework. PAT and the QBD 
framework put forward by the FDA, offer a holistic approach 
to manufacturing pharmaceuticals, emphasising the 
understanding of process variables on the end products 
characteristics and transmitting this information upstream to 
control critical process parameters that effect the critical to 
quality attributes of a product. 
Key components of QBD are discussed and their potential 
impact on current manufacturing processes along with the 
technological capabilities of PAT and the benefits associated 
with real-time process monitoring and control. 
Keywords—quality by design, process analytical technology, 
spectroscopy, chemometrics 
I. INTRODUCTION (HEADING 1) 
Increasing demands in the pharmaceutical industry, in 
conjunction with new developments in medicinal science has 
resulted in the pharmaceutical industries methods of 
manufacturing their products coming under more and more 
scrutiny due to the inefficiencies and wastes associated with 
current manufacturing processes and quality control systems. 
The growing complexity involved in manufacturing newly 
developed products and the decline in the blockbuster drug 
model has placed increasing strain on pharmaceutical 
development and manufacturing process streams. 
At present, the majority of pharmaceutical products are 
manufactured using the batch manufacturing method which 
involves the breakdown of the manufacturing process into 
stages to allow for stage by stage analysis of the material. Upon 
completion of each stage, a sample of material is generally 
extracted from the bulk and analysed in laboratory conditions 
to ensure the critical to quality attributes are in line with 
specifications. The results of the analysis then dictate whether 
the material can be further processed or whether corrective 
actions are required for the material to achieve the desired 
specifications. While the batch method of manufacturing is 
suited to some pharmaceutical products, it remains a tedious 
and inefficient method for other products due to the time and 
labour intensive nature of the sampling and laboratory testing 
which has led for calls within the industry for an innovative 
solution for the manufacturing of pharmaceutical products. 
Process analytical technology (PAT) and the quality by 
design framework (QBD) has been identified as the future of 
pharmaceutical manufacturing and the solution to the 
increasing demand on the industries process stream due to its 
ability to automate the process stream while providing 
information to the user on the optimisation of a given process 
through use of a suite of novel sensors and analysers that 
monitor and control through timely measurements, the critical 
process parameters, that effect the critical to quality attributes. 
This paper focuses on the key components of QBD and 
PAT, their suitability for integration into pharmaceutical 
development and manufacturing and benefits associated with 
the implementation of Process analytical technology in 
conjunction with the quality by design framework. 
II. QUALITY BY DESIGN (QBD) 
In 2009 the ICH pharmaceutical development guideline Q8 
(R2) [1] defined the Quality by Design (QBD) framework as a 
systematic approach to development that begins with 
predefined objectives and emphasises product and process 
understanding and process control, based on sound science and 
quality risk management. Fundamental to the QBD framework 
is the understanding of the raw material attributes and process 
parameters, their effect on the critical to quality attributes 
(CQA) and the identification and control of sources of 
variables within the process [2]. This enables quality to be built 
into manufacturing processes rather than testing for quality in 
finished products, as during development stage, quality issues 
can be analysed for root cause and corrective procedures can be 
implemented accordingly to ensure product end quality. 
The QBD framework is based on 6 fundamental 
components that must be considered prior to the 
implementation of this strategy [3] [4]; 
 Defining the product design goal 
 Determining the critical to quality attributes 
 Risk assessment  
 Developing design space 
 Control strategy 
 Product life cycle management 
Defining the product design goal is the first step in 
implementing QBD and involves evaluating the requirements 
for the products design and performance. These requirements 
are found in the quality target product profile (QTPP) which 
are a set of target specifications set for each individual product. 
The QTPP is used to define the product design and can also be 
used to establish the CQA’s of a product and can serve as a 
guideline throughout the development stage to ensure target 
specifications are achieved [5]. 
Determining the CQA is achieved through evaluation of 
the QTPP and is vital to ensure QBD as the critical to quality 
attributes are the characteristics that directly affect the quality 
of the final product. The framework for the products design 
and process understanding is achieved through the 
identification of the CQA’s. CQA’s can be utilised in the 
developmental risk assessment stage to evaluate root causes of 
quality issues. 
Risk assessments must be carried out to when 
implementing QBD to evaluate the risks associated with 
manufacturing a product. The most influential factors that 
affect the product quality such as process parameters and 
CQA’s must be scrutinised along with all quality control and 
process control systems [4]. 
Developing design space involves the understanding of 
how the combination and interaction of process variables such 
as raw material characteristics and process parameters effect 
the CQA’s. Identification of critical process parameters is 
imperative to ensure process optimisation [3] 
 
Control Strategy is a planned set of goals derived from 
current product and process understanding ,that assures process 
performance and product quality, allowing for identification of 
which material attributes and process parameters should be 
controlled in order to achieve the pre-determined goal of 
product end quality [6]. 
 
Product life cycle management involves implementing 
measures to maintain, improve and control product quality 
through a variety of strong quality control systems that provide 
feedback on product performance such as; 
 Change management and control procedures and 
systems 
 Validation  
 Trending and analysis 
 Training  
 Six Sigma lean manufacturing  
 Quality risk management 
 
Product life cycle management is driven largely by data (both 
qualitative and quantitative), that can be used to highlight 
potential issues in quality, supply chain, material attributes and 
process parameters while also providing information and 
guidance on continuous improvement strategies to enhance 
product quality and performance. 
 
Improper product development strategies and 
manufacturing control systems can have a serious impact on 
product quality and system efficiencies that ultimately effect 
the financial success and performance of a product. The QBD 
framework offers a number of benefits that not only improve 
process understanding, quality and control, but also provides a 
rapid response to manufacturing deviations, improves the 
developmental stage through reducing time and costs and 
reduces FDA approval times. The QBD model is an ideal foil 
for implementing process analytical technology (PAT) due to 
its systematic data driven approach to pharmaceutical 
development and manufacturing.  
III. PROCESS ANALYTICAL TECHNOLOGY (PAT) 
Process analytical technology (PAT) was outlined in 2004 
by the Food and Drug Administration (FDA) as a system for 
designing, analysing and controlling the critical process 
parameters of a manufacturing process that affect the critical to 
quality attributes of raw and in-process materials and processes 
[7]. The use of PAT systems for continuous process monitoring 
and control in the pharmaceutical industry is steadily 
increasing with a number of prominent pharmaceutical 
manufacturers inventing heavily in continuous manufacturing 
facilities [8], [9]. The increasing use of PAT is largely driven 
by increased technological capabilities that provide 
improvements in process monitoring and controls, and the 
FDA’s directives for good manufacturing practices [7], [10], 
[11].  
The goal of PAT is to consistently generate products with a 
predetermined level of quality [12] and enable pharmaceutical 
manufacturers to transition from the tedious and empirical 
methods of batch manufacturing, consisting of time and labour 
intensive off-line sampling and analysis, to a more continuous 
and dynamic method of manufacturing pharmaceuticals where 
process sensors and analysers perform continuous timely 
measurements of critical process parameters (Fig.1) increasing 
end product quality levels [10].  
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Figure 1 Batch Manufacturing Process, Continuous PAT Comparison 
The key to ensuring end product quality is through the 
identification and management of the many variables that exist 
within a manufacturing process such as variations in raw-
material, mechanical performance of processing equipment and 
process parameters and through the scientific understanding of 
how these variables interrelate [13]. 
PAT emphasizes process understanding through the 
identification and real-time monitoring and control of each of 
these variables using specific technological tools such as 
sensors, analysers, probes and optical equipment located at 
predetermined critical measurement points that accumulate 
large data sets. The resulting data is then analysed and 
evaluated using multivariate analysis tools and transposed into 
an electrical signal and fed upstream to adjust plant equipment 
to compensate for variability in raw materials and equipment to 
produce a consistent product. Analysed data can also be 
utilised in continuous improvement strategies on 
manufacturing processes through simulations and process 
modelling that identify key areas within the process that are 
critical to quality. Identification and control of these key areas 
allow for the precise adjustment of plant equipment and raw 
materials allowing for the optimisation and automation of the 
entire process stream [14] and reducing the dependency on off-
line analytics. 
IV. PROCESS MONITORING 
A. Off-line Process Monitoring 
Many of the variables within a process can be measured 
using off-line process monitoring techniques, which generally 
consist of the manual sampling of material from the process, 
for analysis in laboratory conditions. Off-line process 
monitoring has been used extensively in the pharmaceutical 
industry and involves rigorous quality control (QC) procedures 
that must be constantly repeated for each individual process 
such as sample collection, transport, preparation and analysis 
of samples, prior to documentation and archiving of generated 
report documents.  
 
Figure 2 Workflow Diagram of Off-line Sample Analysis [15] 
Laboratories are a critical component of current drug 
manufacturing and require complex, dynamic scheduling and 
skilled personnel to cope with the demands of the supply chain, 
and can have a major impact on the overall supply chain 
service level through its influence on cycle times, delivery 
times and quality levels [16]. The time and labour intensive 
nature of offline laboratory analysis can also be inefficient and 
a waste of valuable resources due to lengthy process time 
frames from sample collection to results of analysis. The 
process of off-line analysis also contains a large portion of non-
value added (NVA) process steps and according to a 2013 
Agilent Technologies survey [15], only 6% of the off-line 
analysis process cycle time is spent on analysis with 27% of 
the time spent on data management and 61% of the time spent 
on sample processing.  
 
Figure 3 Agilent Technologies survey on time allocation of typical offline 
analysis [15] 
The manual aspect of this method of sampling and analysis 
can also be prone to a variety of errors, ranging from human 
error in sample preparation to administrative errors in 
documentation and reporting that can further effect the supply 
chains service level [15], [17]. A reduction in the source of 
these errors can be achieved through the implementation of 
PAT systems in manufacturing processes resulting in real-time 
release testing, improved cycle times and product end quality 
while also relieving pressure on lab analysts. NVA lab 
processes such as data management and administrative duties 
such as documentation and reporting can be significantly 
reduced through on/in/at-line monitoring and control of critical 
process parameters which can reduce the complexity of lab 
scheduling and improve lab performance. 
B. On/In/At-line Process Monitoring 
The central point to PAT is the generation of product 
quality information in real time and the use of that information 
to control the critical process parameters of a manufacturing 
process. Methods of obtaining this information generally 
depend on the process in question and its suitability to various 
process monitoring solutions such as on-line, in-line and at-line 
process monitoring. Evaluation of the critical to quality 
attributes and identification of key measurement points within 
the process generally dictate the suitability of on, in or at-line 
process monitoring critical measurement points within the 
process. 
C. At-Line Process Monitoring 
At-line process monitoring consists of the movement of 
process dedicated testing equipment to the production line. The 
close proximity of the test equipment to the process reduces the 
time lag resulting from the transport and documentation of 
samples from the process to the laboratory. This allows for a 
reduction in the reaction time to perform the necessary counter 
measures to ensure product end quality. It is generally observed 
that at-line process monitoring equipment, while more robust 
and insensitive towards process environments is less precise 
than off-line lab test equipment [18]. 
D. In-Line Process Monitoring 
In-line process monitoring requires no sampling and takes 
timely measurements of material in the process stream through 
use of a variety of either invasive sensors such as immersive 
probes or non-invasive sensors such as optical sensors. 
Advances in fibre optic sensor technology has vastly improved 
the performance of optical sensors for industrial operations and 
is replacing the need for more traditional sensors for process 
monitoring with the ability to measure almost all physical 
measurands of interest [19].  
The wide dynamic range of measurands and remote sensing 
capabilities of fibre optics allow for the removal of expensive 
sensory equipment from or near hazardous environments that 
manufacturing processes generate through use of optical fibres 
embedded at critical process measurement points or through 
immersive fibre optic probes. This allows for precise 
measurement solutions in previously unobtainable or 
undesirable process locations such as areas of extreme 
temperatures, pressures or the measurement of corrosive or 
hazardous materials, resulting in accurate real time data on 
critical to quality attributes to process analysers. 
E. On-line Process Monitoring 
On-line process monitoring involves the redirection of a 
sample of material through automatic extraction systems or 
recirculation loops, where the sampled material is conveyed to 
the sensor locations and either returned to the process stream or 
safely disposed of. This method is generally used in instances 
where modification required for the integration of in-line 
process monitoring is either too costly, impractical or where a 
higher degree of precision is required, as on-line process 
monitoring offers an opportunity to condition the sample 
before analysis to achieve higher quality results [18]. 
To summarize, manufacturing process parameters, raw 
materials, plant equipment and end product quality should be 
carefully evaluated prior to selecting the most suitable process 
monitoring techniques to ensure accurate measurements are 
achieved. Pre-determined measurement locations within a 
manufacturing process may be difficult or impractical to reach, 
consist of extreme environments or pose risks of exposure to 
harmful substances. The variety of process monitoring 
techniques in conjunction with the increasing range and 
versatility of sensory equipment ensures that a viable 
measurement solution can be obtained for the vast majority of 
key measurement locations within a manufacturing process. 
Non-contact sensors, immersive probes and optical sensors can 
provide data on almost every key aspect of the manufacturing 
process such as physical, chemical and biological attributes and 
when integrated into a PAT system through either at/in/on-line 
methods, can provide large continuous data sets to process 
analyser that drive process understanding, optimisation and 
continuous improvement of process and quality. 
V. ANALYTICAL TECHNIQUES 
The discipline of process analytical chemistry has grown 
significantly during the past few decades, due to the increasing 
appreciation for the value of collecting process data [20] 
coupled with the technological advances in computing large 
data sets [21]. As a result, the accuracy, variety and flexibility 
of analytical techniques used in the pharmaceutical industry 
has steadily improved. The most commonly used analytical 
techniques in pharmaceutical manufacturing, development and 
analytical chemistry is spectroscopy and chromatography. 
There is a wide variety of both spectroscopy and 
chromatography techniques in use in industry such as NIR, 
MIR and Raman spectroscopy and high performance liquid 
chromatography (HPLC), gas chromatography and thin layer 
chromatography. For the purpose of this paper, the focus will 
be on NIR spectroscopy and Raman spectroscopy due to their 
non-contact, non-destructive and remote sensing capabilities 
that can provide real-time data on a wide range of physical, 
chemical and biological properties in a manufacturing process 
and their suitability for integration into PAT systems. 
 
A. NIR Spectroscopy 
NIR spectroscopy is a simple non-contact, non-destructive 
analytical technique that can provide multi-constituent analysis 
on virtually any matrix while providing levels of accuracy 
comparable to that of primary reference methods [22]. The low 
absorption co-efficient of NIR’s allows for deep penetration of 
the radiation in the sample that can provide information on 
both sample thickness and volume parameters [23], [24] while 
providing real time, precise and repeatable measurements 
requiring no sample preparation. Another advantage of the 
penetration depth of NIR’s is the increased volume of material 
that is analysed reduces sampling error in the system [25]. NIR 
absorption spectra can often be complex due to the overlapping 
NIR absorption bands and require mathematical procedures 
such as chemometric data processing for data for analysis.  
NIR spectroscopy techniques are becoming the most widely 
used analytical technique due to their ability to be placed off-
line, at-line, on-line or in-line [26] using optical couplings that 
allow for easy integration into manufacturing process streams. 
For continuous monitoring of manufacturing processes NIR 
spectroscopy has been successfully deployed online to monitor 
a number of processes in the pharmaceutical industry [27] [28] 
such as; 
 Reaction monitoring, monitoring the chemical reactions 
of liquids and solids 
 Powder blending, measuring blend homogeneity in a 
bulk solid 
 Solvent monitoring, monitoring the mixture of solvents 
in a solvent recovery process 
 Moisture measurements, measuring the amount of 
moisture during granulation, drying, and purification 
stages of solids  
 
NIR is an important PAT tool for continuous monitoring 
when utilised in conjunction with multivariate and statistical 
analysis tools and can provide both qualitative and quantitative 
assessments of materials composition and chemical reactions. 
The data acquired from NIR spectroscopic techniques can then 
be utilised for continuous improvement and optimisation of 
both process control and product quality. 
B. Raman Spectroscopy 
Raman spectroscopy has been an established analytical 
method in pharmaceutical development and general analytical 
chemistry for many years used to provide a fingerprint by 
which molecules can be identified. Similarly to NIR, Raman 
spectroscopy is a non-contact, non-destructive analytical 
technique with remote sensing capabilities that utilises fibre 
optics to integrate into process streams and hazardous 
environments.   
The principle of operation of Raman spectroscopy is based 
on the inelastic scattering of monochromatic light, usually from 
a laser that interacts with molecular vibrations, phonons or 
other excitation systems [29]. When light interacts with a 
material, the light energy is altered and the frequency changes, 
the resulting Raman effect is weak and requires highly 
sensitive spectrometers to analyse the effect and produce data. 
Raman spectroscopy is the most widely used analytical 
technique in pharmaceutical development due to its ability to 
rapidly characterize the chemical composition and structure of 
a solid, liquid, gas, gel, slurry or powder sample through 
providing detailed characteristics of their vibrational 
transitions. The interpretation of data is also easier than that of 
NIR spectroscopy and does not compulsorily call for 
multivariate modelling as simple modelling of the peak heights 
or ratios can often achieve the desired goals [30]. 
Raman spectroscopy is ideally suited for application in 
PAT systems due to the flexibility of the technique to operate 
online or inline whilst providing accurate and repeatable real-
time measurements of materials under process and providing 
both quantitative and qualitative data to enhance process 
monitoring and control. Typical applications of Raman 
spectroscopy in the pharmaceutical include [31]; 
 Blend uniformity 
 Active pharmaceutical ingredient (API) concentration 
measurements 
 Raw material verification 
 Contamination & impurity measurements 
Recent advances in Raman spectroscopy has increased the 
versatility and suitability of this technique for application in 
continuous process monitoring systems such as PAT. The 
proven accuracy and precision of these instruments allow them 
to be utilised in highly regulated industries such as 
pharmaceutical development and analytical chemistry to 
provide real time data on key characteristics of materials for 
continuous process monitoring and continuous process 
improvement strategies. 
C. Selection of Process Analysers 
While similarities exist with NIR and Raman spectroscopy 
there are some fundamental differences between the two 
methods that effect their suitability to certain applications, 
however the complimentary nature of NIR and Raman 
spectroscopy ensures that the vast majority of measurement 
applications would be suitable to at least one of the two 
aforementioned techniques. This is due to the fact that strong 
bands in the IR spectrum correspond to weak bands in the 
Raman spectrum and vice versa [32].  
NIR and Raman spectroscopy both offer a non-contact, 
non-destructive form of real time measurements that require no 
sample preparation and are both easily integrated into 
manufacturing processes while also providing remote sensing 
capabilities.  
Raman spectroscopy is used for highly specific analyses of 
materials and for analysis of liquids and generally requires 
simple statistical modelling to interpret the acquired data, 
however as the Raman affect is weak, expensive and highly 
accurate equipment is required for detection. Fluorescence 
from impurities and heating of the sample from laser radiation 
can obstruct the Raman spectrum and equipment must be 
carefully tuned and calibrated to counteract these effects [33]. 
NIR spectroscopy is used in the pharmaceutical industry to 
provide rapid measurements in areas such as raw material 
identification and classification, blend homogeneity and 
particle sizing and requires multivariate statistical analysis 
techniques to interpret the data collected from in process 
materials. NIR spectroscopic instrumentation, in comparison to 
that of Raman is relatively simplistic and inexpensive while 
maintaining a high level of precision, repeatability and 
accuracy. Its penetration depth into sampled material can also 
reduce percentage error as a larger portion of the material can 
be analysed. 
There are a number of key factors to consider prior to 
selecting the correct spectroscopic technique for integration in 
PAT systems, such as the critical to quality attributes of the 
material, levels of accuracy or error tolerances required, 
chemical and physical stability of the material, process 
parameters and environment and the level and method of 
chemometrics required. Understanding these key factors allows 
for selection of the correct technique to ensure optimum levels 
of performance in an integrated PAT system [34].  
VI. CHEMOMETRICS 
Chemometrics is one of the most critical aspects to PAT 
systems and is used to extract, analyse and interpret chemical 
information from materials under process through use of 
mathematical and statistical methods and is driven primarily 
from physical and spectral data. The data, acquired from 
sensors and analyser located at key measurement points within 
the process, is computationally analysed using a variety of 
mathematical and statistical tools and simulations. This allows 
for a more in-depth understanding of chemical information and 
the correlation of quality parameters or physical properties of 
materials to instrument data [35]. 
Analysis of the data is achieved using specialised software 
packages consisting of a variety of multivariate, univariate and 
statistical analysis tools that are suited to a variety of 
applications in materials processing such as [36]; 
 Identification of critical to quality attributes 
 Identification of multifactorial relationships between 
process variables 
 Spectroscopic calibration solutions 
 Statistical modelling for process optimisation  
 Multivariate statistical process control 
 Process modelling for continuous monitoring and fault 
detection 
The fundamental principle of chemometrics is the 
acquisition of data, and with advances in measurement sciences 
and computational capabilities of data acquisition systems, it is 
possible to obtain and input extremely large data sets from 
sensors and analysers located within the process stream of 
manufacturing processes into chemometric software packages. 
This allows for a previously unachievable level of process 
understanding and control and drives innovation in 
pharmaceutical development and manufacturing. 
VII. CONCLUSION 
The pharmaceutical industry is experiencing a period of 
sustained growth since 2001 and continues to thrive through 
investments in the research and development of innovative 
treatments, biotechnology and biologics among others. In 2013 
a report issued by the IMS institute on the global use of 
medicines stated that, global spending on pharmaceuticals will 
exceed €1.2 trillion by 2017 [37], [38] which will see the 
industry having tripled in size over a 16 year span. With 
increasing strain placed on supply chains and the decline of the 
blockbuster drug model, pharmaceutical manufacturers in 
recent years have begun to invest heavily in strategies and 
techniques to reduce product development times and costs 
while improving manufacturing efficiency, product quality and 
process understanding. 
The QBD framework in conjunction with PAT systems 
backed by the FDA, not only offer a solution to continuous 
process monitoring and control but offer a systematic and data 
driven approach to pharmaceutical development and validation 
that acts as a guidance to pharmaceutical manufacturers that 
can reduce FDA approval times and increase the likelihood that 
FDA submission guidelines and specifications are achieved.  
PAT systems, enveloped in the QBD framework provide 
the majority of this data through a variety of sensors and 
analysers that have advanced technologically in recent years to 
a degree where almost every aspect of a processes chemical, 
physical and biological characteristics can be analysed 
monitored and controlled. Advances in analytical chemistry 
such as chemometrics and the computational capabilities of 
equipment has provided analysts with previously unobtainable 
level of process understanding that can be applied to 
continuous improvement strategies, process optimisation and 
increased product quality measures. 
In conclusion QBD and PAT offer wide ranging benefits to 
both pharmaceutical development and manufacturing through 
reduction in product approval times, increased product quality, 
significant reduction in cycle times due to on/inline process 
monitoring and significant financial gains as a result of reduced 
labour dependencies and increased efficiencies. 
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